Corrigendum to “Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis” [Pharmacol. Res. 188 (2023) 106668]
oleh: Tianyao Lei, Tianwei Xu, Niu Zhang, Xiaoteng Zou, Ziyue Kong, Chenchen Wei, Zhaoxia Wang
| Format: | Article |
|---|---|
| Diterbitkan: | Elsevier 2023-10-01 |
Deskripsi
No description available for this item.